10 Big Names Beating Wall Street at its Own Game

6. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellia Therapeutics soared to a new all-time high on Monday, despite the lack of catalysts to boost buying appetite.

During the session, the stock soared to its highest 52-week price of $27.98 before paring gains to end the day just up by 13.05 percent at $27.98 apiece.

Earlier this month, Intellia Therapeutics, Inc. (NASDAQ:NTLA) earned an overall bullish sentiment from two investment companies, on strong optimism for its earnings and hereditary angioedema (HAE) program.

In a market note earlier, JMP Securities gave an “outperform” rating for the stock with a price target of $33, or an upside potential of 17.9 percent from its latest closing price.

According to the investment firm, the company’s drug candidate, lonvo-Z, could capture a 19-percent market share and potentially translate to $2.8 billion market opportunity.

Topline data are expected in the first half of 2026, while a biologics license application (BLA) is targeted to be submitted in the second half of 2026.

If and when approved by the Food and Drug Administration, Intellia Therapeutics, Inc. (NASDAQ:NTLA) is scheduled to launch the drug in the first half of 2027.